Registration for a live webinar on 'Gamma-delta T cells for immunotherapy of cancer' is now open.See webinar details
Clinical proteomics in gastrointestinal cancers
Published on November 13, 2013 37 min
Other Talks in the Series: Clinical Proteomics
Urinary proteomics in kidney and cardiovascular disease
- Prof. Harald Mischak
- University of Glasgow, UK
Proteomics in kidney disease: clinical considerations
- Prof. Peter Rossing
- Steno Diabetes Center, Denmark
Hello. My name is Jochen Metzger and I am working at Mosaiques Diagnostics, located in Hannover, Germany. Mosaiques Diagnostics is a small company specializing in clinical proteomics and capillary electrophoresis-mass spectrometry, currently the most advanced technology to identify disease-specific polypeptide biomarkers in body fluids. My presentation is about clinical proteomics in gastrointestinal cancers, describing the results of clinical studies which were carried out in close collaboration with the Gastroenterology Department of the Medical School Hannover, and under the supervision of Tim Lankisch and Michael Manns.
In this talk, I want to focus on tumors of the biliary tract and the pancreas. The clinical studies presented in this study will focus on the following clinical needs. In the case of cholangiocarcinoma, it's accurate detection in patients that present to the gastrointestinal endoscopy unit with suspicion of cholangiocarcinoma due to biliary stenosis is of utmost importance to select the most appropriate therapy. Superior, early, and accurate cholangiocarcinoma detection is especially required in young patients with primary sclerosing cholangitis, who are at risk for this highly aggressive type of bile duct cancer, since this will enable early curative treatment. In the case of pancreatic carcinoma, its reliable differentiation from chronic pancreatitis, a long-term inflammatory process that shows the same signs in the pancreas, is of high clinical value. Moreover, in the elucidation of underlying pathological processes in pancreatic cancer, progression is attempted to provide new insights into the treatment of this cancer.